From Actavis To Allergan: One Pharma Company's Wild Dealmaking Journey
Allergan, a company shaped by five major deals since 2012, is a symbol of the pharmaceutical industry’s recent merger-mania.
For a master class in mergers and acquisitions, one need only look at the company formerly known as Actavis. Now called Allergan, after its $70 billion acquisition of that maker of Botox last fall, the pharmaceutical firm has undertaken a dizzying series of deals in just the last few years, reinventing and renaming itself in a fashion that might make the artist formerly known as The Artist Formerly Known As Prince proud. This week alone, Allergan AGN -2.70% announced plans to sell its generics business to Teva Pharmaceutical Industries TEVA -2.55% and to scoop up biopharma firm Naurex. (For more on the frenzy of transformational M&A deals in the drug industry, see: “The real reasons for the pharma merger boom.”)
Hey, check out all the research scientist jobs. Post your resume today!
For a master class in mergers and acquisitions, one need only look at the company formerly known as Actavis. Now called Allergan, after its $70 billion acquisition of that maker of Botox last fall, the pharmaceutical firm has undertaken a dizzying series of deals in just the last few years, reinventing and renaming itself in a fashion that might make the artist formerly known as The Artist Formerly Known As Prince proud. This week alone, Allergan AGN -2.70% announced plans to sell its generics business to Teva Pharmaceutical Industries TEVA -2.55% and to scoop up biopharma firm Naurex. (For more on the frenzy of transformational M&A deals in the drug industry, see: “The real reasons for the pharma merger boom.”)
Hey, check out all the research scientist jobs. Post your resume today!